324 related articles for article (PubMed ID: 27860118)
1. Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis.
Umemura T; Sekiguchi T; Joshita S; Yamazaki T; Fujimori N; Shibata S; Ichikawa Y; Komatsu M; Matsumoto A; Shums Z; Norman GL; Tanaka E; Ota M
Liver Int; 2017 Jun; 37(6):897-905. PubMed ID: 27860118
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis.
Shi TY; Zhang LN; Chen H; Wang L; Shen M; Zhang X; Zhang FC
World J Gastroenterol; 2013 Feb; 19(7):1111-8. PubMed ID: 23467321
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
John BV; Khakoo NS; Schwartz KB; Aitchenson G; Levy C; Dahman B; Deng Y; Goldberg DS; Martin P; Kaplan DE; Taddei TH
Am J Gastroenterol; 2021 Sep; 116(9):1913-1923. PubMed ID: 33989225
[TBL] [Abstract][Full Text] [Related]
4. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
6. Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems.
Goel A; Kim WR
Clin Liver Dis; 2018 Aug; 22(3):563-578. PubMed ID: 30259853
[TBL] [Abstract][Full Text] [Related]
7. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
[TBL] [Abstract][Full Text] [Related]
9. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
[TBL] [Abstract][Full Text] [Related]
13. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
[TBL] [Abstract][Full Text] [Related]
14. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.
Harms MH; Lammers WJ; Thorburn D; Corpechot C; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Dalekos GN; Bruns T; Parés A; Mason AL; Verhelst X; Kowdley KV; Goet JC; Hirschfield GM; Hansen BE; van Buuren HR;
Am J Gastroenterol; 2018 Feb; 113(2):254-264. PubMed ID: 29231188
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
van Hoogstraten HJ; Hansen BE; van Buuren HR; ten Kate FJ; van Berge-Henegouwen GP; Schalm SW
J Hepatol; 1999 Aug; 31(2):256-62. PubMed ID: 10453938
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients.
Namisaki T; Moriya K; Kitade M; Kawaratani H; Takeda K; Okura Y; Takaya H; Nishimura N; Seki K; Kaji K; Sato S; Sawada Y; Yamao J; Mitoro A; Uejima M; Mashitani T; Shimozato N; Nakanishi K; Furukawa M; Saikawa S; Kubo T; Yoshiji H
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):23-30. PubMed ID: 27755231
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
[TBL] [Abstract][Full Text] [Related]
18. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
19. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
20. Predicting outcome in primary biliary cirrhosis.
Lammers WJ; Kowdley KV; van Buuren HR
Ann Hepatol; 2014; 13(4):316-26. PubMed ID: 24927602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
